Cite
Ballard JE, Pall PS, Vardigan J, et al. Translational Pharmacokinetic-Pharmacodynamic Modeling of NaV1.7 Inhibitor MK-2075 to Inform Human Efficacious Dose. Front Pharmacol. 2021;12:786078doi: 10.3389/fphar.2021.786078.
Ballard, J. E., Pall, P. S., Vardigan, J., Zhao, F., Holahan, M. A., Zhou, X., Jochnowitz, N., Kraus, R. L., Klein, R. M., Henze, D. A., Houghton, A. K., Burgey, C. S., Gibson, C., & Struyk, A. (2021). Translational Pharmacokinetic-Pharmacodynamic Modeling of NaV1.7 Inhibitor MK-2075 to Inform Human Efficacious Dose. Frontiers in pharmacology, 12786078. https://doi.org/10.3389/fphar.2021.786078
Ballard, Jeanine E, et al. "Translational Pharmacokinetic-Pharmacodynamic Modeling of NaV1.7 Inhibitor MK-2075 to Inform Human Efficacious Dose." Frontiers in pharmacology vol. 12 (2021): 786078. doi: https://doi.org/10.3389/fphar.2021.786078
Ballard JE, Pall PS, Vardigan J, Zhao F, Holahan MA, Zhou X, Jochnowitz N, Kraus RL, Klein RM, Henze DA, Houghton AK, Burgey CS, Gibson C, Struyk A. Translational Pharmacokinetic-Pharmacodynamic Modeling of NaV1.7 Inhibitor MK-2075 to Inform Human Efficacious Dose. Front Pharmacol. 2021 Dec 24;12:786078. doi: 10.3389/fphar.2021.786078. eCollection 2021. PMID: 35002718; PMCID: PMC8740778.
Copy
Download .nbib